SynthesisInternational journal of clinical oncology2022
Clinical practice guideline for the treatment of malignant ascites: section summary in Clinical Practice Guideline for peritoneal dissemination (2021).
Synthesis in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Does Malignant Ascites Define Prognosis in Gastric Cancer with Peritoneal Spread? A Systematic Review and Meta-analysis.Journal of gastrointestinal cancer · 2025Pooled it
- Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study).Technology in cancer research & treatmentTrial
- Endostar combined with docetaxel or cisplatin in the management of malignant ascites through hyperthermic intraperitoneal chemotherapy: A retrospective cohort study.Oncology letters · 2026Article
- Usefulness of cell-free and concentrated pleural effusion reinfusion therapy in terminal cancer patients.Fujita medical journal · 2026Article
- Significance of Serum Tumor Markers in Esophageal and Gastric Cancers: A Systematic Literature Review.Annals of gastroenterological surgery · 2026Review
- Correlation of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio with serum-ascites albumin gradient in ascites.Bioinformation · 2026Article
- Clinical Outcomes and Healthcare Costs of CART Versus Paracentesis for Malignant Ascites: A Nationwide Retrospective Cohort Study in Japan.Cancer medicine · 2026Article
- Upfront Cytoreductive Surgery as a Bridge to Systemic Therapy for Recurrent Peritoneal Dissemination of Ovarian Angiosarcoma: A Pediatric Case Report.Surgical case reports · 2026Article
- Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors.Experimental hematology & oncology · 2025Article
- Biomarker-guided strategy for Denver peritoneovenous shunts in refractory ascites: a retrospective single-center study.Langenbeck's archives of surgery · 2025Article
- Article
- Cytokine dynamics and quality of life: unraveling the impact of cell-free and concentrated ascites reinfusion therapy in ovarian cancer patients.International journal of clinical oncology · 2025Article
- Lavage cytology diagnosed by immunostaining may be a poor prognostic factor in pathological stage III colorectal cancer.Annals of gastroenterological surgery · 2025Article
- Advances in the treatment of malignant ascites in China.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Review
- Is Low Volume Drainage of Ascites Associated With Improved Survival in Digestive System Cancer Patients With Malignant Ascites?-A Retrospective Cohort Study.Journal of palliative care · 2023Article
- Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review.Pharmaceutics · 2023Review
- Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces-A Review.Pharmaceutics · 2023Review
- Utility of ascitic tumor markers and adenosine deaminase for differential diagnosis of tuberculous peritonitis and peritoneal carcinomatosis.BMC gastroenterology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with peritoneal dissemination (PD) caused by abdominal malignancies are often associated with massive ascites, which shows extremely dismal prognosis because of the discontinuation of systemic chemotherapy mostly due to poor performance status. Many treatment methods, such as simple drainage, peritoneovenous shunting (PVS) and cell-free and concentrated reinfusion therapy (CART), have been used for symptom relief. However, the clinical efficacies of these methods have not been fully investigated yet. Recently, we developed the Clinical Practice Guideline for PD caused by various malignancies according to "Minds Clinical Practice Guideline Development Guide 2017". In this guideline, we systematically reviewed information on clinical diagnosis and treatments for PD using PubMed databases (2000 - 2020), and clarified the degree of recommendation for clinical questions (CQ). The evidence level was divided into groups by study design and quality. The literature level and a body of evidence were evaluated in reference to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Based on the results of systematic review, the strength of the recommendations was evaluated at a consensus meeting of the Guideline Committee. This is the English synopsis of the part of treatment of malignant ascites in Clinical Practice Guideline for PD, 2021 in Japanese. The guidelines summarize the general aspect of the treatment of malignant ascites and statements with recommendation strengths, evidence levels, agreement rates and future perspective for four raised clinical questions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.